Rare single PML::RARA fusion transcript from insertion on derivative chromosome 17 in acute promyelocytic leukemia

Hematological malignancies often involve specific chromosomal rearrangements that disrupt normal cellular differentiation and promote uncontrolled proliferation. Prior research has shown that over ninety percent of individuals diagnosed with acute promyelocytic leukemia (APL) possess a reciprocal translocation between chromosomes 15 and 17. This classic genetic event typically generates two distinct chimeric genes known as PML::RARA and RARA::PML through the fusion of the promyelocytic leukemia gene and the retinoic acid receptor alpha gene. While the oncogenic role of the first fusion is well-documented, the functional necessity of the reciprocal transcript remains a subject of intense investigation within molecular oncology. Rare variants involving complex insertions or cryptic rearrangements occasionally challenge the standard dual-fusion paradigm by presenting isolated genetic markers. Understanding these atypical cases provides unique insights into the minimal genetic requirements for leukemic transformation and the specific targets of modern chemotherapy. This absence of evidence motivated the detailed characterization of a patient presenting with an isolated fusion event on a derivative chromosome.

This investigation characterizes a rare molecular subtype of acute promyelocytic leukemia involving a solitary PML::RARA fusion transcript located on derivative chromosome 17. The researchers sought to determine if the absence of the reciprocal RARA::PML transcript affects the clinical presentation or the subsequent therapeutic response to standard induction agents. Identifying the specific chromosomal location of the insertion on derivative chromosome 17 served as a primary objective to clarify the underlying cytogenetic mechanism. The study evaluates the efficacy of standard induction therapy in the context of this atypical genetic architecture to ensure treatment protocols remain valid. By documenting this fourth known instance of a single fusion, the report clarifies the essential drivers of myeloid pathogenesis in the absence of typical translocations. The work aims to confirm whether the PML::RARA chimeric protein alone suffices to initiate and maintain the leukemic phenotype in human subjects. Finally, the analysis explores the implications of these findings for the broader understanding of retinoic acid receptor signaling in malignant cells.

Clinical assessment focused on a patient exhibiting the morphological and hematological features characteristic of acute promyelocytic leukemia. Cytogenetic analysis utilized standard karyotyping and fluorescence in situ hybridization to identify the presence of derivative chromosome 17 and other structural variations. Molecular testing screened for the dual fusion transcripts typically associated with the t(15;17) translocation using reverse transcription polymerase chain reaction. The medical team administered a combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) as the primary therapeutic intervention for remission induction. Clinicians monitored the patient's hematological response and molecular status to evaluate the sensitivity of the single-fusion variant to these targeted agents. Comparative analysis with the three previously reported cases provided a broader context for the observed clinical outcomes and genetic findings. This methodological approach ensured a comprehensive evaluation of the patient's unique molecular profile and the effectiveness of the chosen pharmacological strategy.

Molecular profiling revealed a single PML::RARA fusion transcript resulting from a rare insertion event on derivative chromosome 17. Testing confirmed the complete absence of the reciprocal RARA::PML transcript, which is present in the vast majority of acute promyelocytic leukemia cases. The patient achieved a favorable clinical response following the administration of all-trans-retinoic acid and arsenic trioxide, reaching complete hematological remission. This successful outcome demonstrates that the solitary fusion protein remains highly sensitive to standard targeted therapies despite the lack of a reciprocal partner. Data analysis identifies this presentation as only the fourth documented case of its kind in the global medical literature. The findings highlight that the PML::RARA transcript acts as the dominant oncogenic driver and the primary therapeutic target in this specific leukemic lineage. Statistical comparisons suggest that the clinical behavior of this rare variant mirrors that of the more common dual-fusion translocation.

The study establishes that the PML::RARA fusion transcript is the fundamental requirement for the development and maintenance of acute promyelocytic leukemia. These observations suggest that the RARA::PML reciprocal transcript is not essential for the initiation of leukemogenesis or the survival of malignant promyelocytes. Targeted therapies like arsenic trioxide and all-trans-retinoic acid effectively neutralize the primary oncogenic product regardless of the presence of the reciprocal fusion. Future diagnostic protocols should account for rare insertion events that produce isolated fusion signals on derivative chromosomes to avoid misdiagnosis. This case reinforces the importance of precise molecular characterization in guiding treatment decisions for atypical leukemia variants that do not follow standard patterns. Clinicians can expect standard therapeutic regimens to remain effective in patients lacking the RARA::PML chimeric gene, ensuring consistent care across molecular subtypes. The research underscores the necessity of ongoing surveillance for rare genetic variants to refine our understanding of leukemic drivers.